hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study
BackgroundCurrently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor and there are no biomarkers. hPG80 (circulating progastrin) secreted into the blood by tumor cells has been widely studied in colorectal cancer. Its involvement in tumorigenesis has b...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.1073476/full |
| _version_ | 1797956005752995840 |
|---|---|
| author | Melanie Casile Melanie Casile Melanie Casile Judith Passildas Judith Passildas Judith Passildas Bérengère Vire Ioana Molnar Ioana Molnar Ioana Molnar Xavier Durando Xavier Durando Xavier Durando Xavier Durando |
| author_facet | Melanie Casile Melanie Casile Melanie Casile Judith Passildas Judith Passildas Judith Passildas Bérengère Vire Ioana Molnar Ioana Molnar Ioana Molnar Xavier Durando Xavier Durando Xavier Durando Xavier Durando |
| author_sort | Melanie Casile |
| collection | DOAJ |
| description | BackgroundCurrently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor and there are no biomarkers. hPG80 (circulating progastrin) secreted into the blood by tumor cells has been widely studied in colorectal cancer. Its involvement in tumorigenesis has been demonstrated in the literature. Moreover, according to a recent study, hPG80 is expressed in the blood of cancer patients at a significantly higher concentration than in the control group composed of healthy blood donors.MethodsThe PROGLIO study is a pilot, single-center, longitudinal study that primarily seeks to evaluate circulating plasma hPG80 concentrations over time in patients with high-grade glial tumors. A fasting blood sample will be taken on the start and end day of radiotherapy and during the adjuvant chemotherapy (every 3 cycles). Follow-up monitoring will be performed for 9 months, with a blood sample taken every 3 months on the day of the follow-up MRI. The study plans to recruit 30 patients and recruitment started in February 2022.Trial registrationClinicalTrials.gov, ID NCT05157594; registered on October 27, 2021. |
| first_indexed | 2024-04-10T23:43:08Z |
| format | Article |
| id | doaj.art-e9828b953dd042f88e7191a6bdaeddf3 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-10T23:43:08Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-e9828b953dd042f88e7191a6bdaeddf32023-01-11T06:15:44ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-01-011310.3389/fneur.2022.10734761073476hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot studyMelanie Casile0Melanie Casile1Melanie Casile2Judith Passildas3Judith Passildas4Judith Passildas5Bérengère Vire6Ioana Molnar7Ioana Molnar8Ioana Molnar9Xavier Durando10Xavier Durando11Xavier Durando12Xavier Durando13INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, FranceUMR 501, Clinical Investigation Centre, Clermont-Ferrand, FranceClinical Research and Innovation Department, Centre Jean Perrin, Clermont-Ferrand, FranceINSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, FranceUMR 501, Clinical Investigation Centre, Clermont-Ferrand, FranceClinical Research and Innovation Department, Centre Jean Perrin, Clermont-Ferrand, FranceBIODENA CARE, Montpellier, FranceINSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, FranceUMR 501, Clinical Investigation Centre, Clermont-Ferrand, FranceClinical Research and Innovation Department, Centre Jean Perrin, Clermont-Ferrand, FranceINSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, FranceUMR 501, Clinical Investigation Centre, Clermont-Ferrand, FranceClinical Research and Innovation Department, Centre Jean Perrin, Clermont-Ferrand, FranceOncology Department, Centre Jean Perrin, Clermont-Ferrand, FranceBackgroundCurrently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor and there are no biomarkers. hPG80 (circulating progastrin) secreted into the blood by tumor cells has been widely studied in colorectal cancer. Its involvement in tumorigenesis has been demonstrated in the literature. Moreover, according to a recent study, hPG80 is expressed in the blood of cancer patients at a significantly higher concentration than in the control group composed of healthy blood donors.MethodsThe PROGLIO study is a pilot, single-center, longitudinal study that primarily seeks to evaluate circulating plasma hPG80 concentrations over time in patients with high-grade glial tumors. A fasting blood sample will be taken on the start and end day of radiotherapy and during the adjuvant chemotherapy (every 3 cycles). Follow-up monitoring will be performed for 9 months, with a blood sample taken every 3 months on the day of the follow-up MRI. The study plans to recruit 30 patients and recruitment started in February 2022.Trial registrationClinicalTrials.gov, ID NCT05157594; registered on October 27, 2021.https://www.frontiersin.org/articles/10.3389/fneur.2022.1073476/fullprogastrinhPG80high grade glial tumorsbiomarkerbrain cancer |
| spellingShingle | Melanie Casile Melanie Casile Melanie Casile Judith Passildas Judith Passildas Judith Passildas Bérengère Vire Ioana Molnar Ioana Molnar Ioana Molnar Xavier Durando Xavier Durando Xavier Durando Xavier Durando hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study Frontiers in Neurology progastrin hPG80 high grade glial tumors biomarker brain cancer |
| title | hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study |
| title_full | hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study |
| title_fullStr | hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study |
| title_full_unstemmed | hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study |
| title_short | hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study |
| title_sort | hpg80 circulating progastrin as a blood biomarker for high grade glial tumors a pilot study |
| topic | progastrin hPG80 high grade glial tumors biomarker brain cancer |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.1073476/full |
| work_keys_str_mv | AT melaniecasile hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT melaniecasile hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT melaniecasile hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT judithpassildas hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT judithpassildas hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT judithpassildas hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT berengerevire hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT ioanamolnar hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT ioanamolnar hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT ioanamolnar hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT xavierdurando hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT xavierdurando hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT xavierdurando hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy AT xavierdurando hpg80circulatingprogastrinasabloodbiomarkerforhighgradeglialtumorsapilotstudy |